New
HealthMore in Health →
Daiichi Sankyo Takes Nearly $1 Billion Hit After Pulling Back ADC Capacity Plans
Daiichi Sankyo said it is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an extraordinary loss of 149.4 billion yen after overestimating demand, highlighting the risks of expanding
Key Takeaways
- Daiichi Sankyo reported an extraordinary loss of 149.4 billion yen, roughly $950 million.
- The loss was tied to overestimating demand for antibody-drug conjugate manufacturing capacity.
DE
DT Editorial AI··via endpoints.news